ADIPOQ and rheumatoid arthritis: Another recent study showed that tocilizumab treatment of RA patients with active RA despite previous conventional synthetic disease-modifying antirheumatoic drug (DMARD) and/or biological DMARD treatment was associated with an increase in total and HMW adiponectin, especially early after treatment onset, then declining until month 6 to 12 [52].